MAR Stock Overview A life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Maravai LifeSciences Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Maravai LifeSciences Holdings Historical stock prices Current Share Price US$5.00 52 Week High US$10.50 52 Week Low US$4.00 Beta -0.077 1 Month Change -9.91% 3 Month Change -29.58% 1 Year Change -16.67% 3 Year Change -85.84% 5 Year Change n/a Change since IPO -83.51%
Recent News & Updates
Maravai LifeSciences Holdings, Inc. Announces Board Changes Dec 06
Now 21% undervalued after recent price drop Nov 16
Co-Founder & Executive Chairman recently bought €927k worth of stock Nov 15
Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.049 loss in 3Q 2023) Nov 09
Maravai LifeSciences Holdings, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2024 Nov 09 Maravai LifeSciences Holdings, Inc. Updates Revenue Guidance for the Year 2024 See more updates
Maravai LifeSciences Holdings, Inc. Announces Board Changes Dec 06
Now 21% undervalued after recent price drop Nov 16
Co-Founder & Executive Chairman recently bought €927k worth of stock Nov 15
Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.049 loss in 3Q 2023) Nov 09
Maravai LifeSciences Holdings, Inc. Reports Unaudited Impairment Charges for the Third Quarter Ended September 30, 2024 Nov 09 Maravai LifeSciences Holdings, Inc. Updates Revenue Guidance for the Year 2024
Maravai LifeSciences Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 16
Second quarter 2024 earnings released: US$0.056 loss per share (vs US$0.05 loss in 2Q 2023) Aug 08
Maravai Lifesciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024 Aug 08
Maravai Lifesciences Holdings, Inc. Appoints William “Trey” Martin, Iii to Board of Directors, Effective from July 31, 2024 Jul 30
Maravai LifeSciences Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 11
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Small Cap Comp Value Index Jul 03
Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024 Jun 13
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024 May 10
First quarter 2024 earnings released: US$0.091 loss per share (vs US$0.001 loss in 1Q 2023) May 09
Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024 Apr 28
Maravai LifeSciences Holdings, Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 11
Full year 2023 earnings released: US$0.90 loss per share (vs US$1.67 profit in FY 2022) Feb 23
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Feb 23
Investor sentiment deteriorates as stock falls 16% Feb 02
Maravai LifeSciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Jan 30
Third quarter 2023 earnings released: US$0.049 loss per share (vs US$0.34 profit in 3Q 2022) Nov 09
Now 27% undervalued after recent price drop Nov 09
Maravai LifeSciences Holdings, Inc. Provides Updated Earnings Guidance for the Full Year 2023 Nov 08
Maravai LifeSciences Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 18
Investor sentiment deteriorates as stock falls 15% Oct 11
Maravai Lifesciences Holdings, Inc. Provides Earnings Guidance for the Year 2023 Aug 09
New minor risk - Profit margin trend Aug 08
Second quarter 2023 earnings released: US$0.05 loss per share (vs US$0.54 profit in 2Q 2022) Aug 08
Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer Jul 29
Maravai LifeSciences Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Maravai LifeSciences Holdings, Inc. Announces Board Changes Jul 23
New major risk - Share price stability Jul 05
Investor sentiment improves as stock rises 25% May 16
First quarter 2023 earnings released: US$0.001 loss per share (vs US$0.51 profit in 1Q 2022) May 09
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Year 2023 May 09
Full year 2022 earnings released: EPS: US$1.67 (vs US$1.59 in FY 2021) Feb 24
Maravai LifeSciences Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 02
Investor sentiment deteriorated over the past week Dec 07 Maravai LifeSciences Holdings, Inc. Announces Executive Changes
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.46 in 3Q 2021) Nov 03
Investor sentiment deteriorated over the past week Oct 25
Maravai Lifesciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Oct 20
Maravai LifeSciences Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 19
Investor sentiment deteriorated over the past week Oct 10
Maravai LifeSciences Announces CEO Leadership Transition Oct 04
Investor sentiment improved over the past week Sep 26
Maravai Lifesciences Holdings, Inc. Provides Revenue Guidance for 2022 Aug 06
Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.44 in 2Q 2021) Aug 05
Maravai LifeSciences Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 20
Maravai LifeSciences, Inc. Appoints Peter Leddy as Executive Vice President and Chief Administrative Officer Jun 28
Investor sentiment deteriorated over the past week Jun 14
First quarter 2022 earnings released: EPS: US$0.51 (vs US$0.24 in 1Q 2021) May 06
Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2022 May 06
High number of new and inexperienced directors Apr 27
Maravai LifeSciences Holdings, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 12, 2022 Apr 15
Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay Apr 13
Investor sentiment improved over the past week Mar 02
Maravai Lifesciences Holdings, Inc. Revised Revenue Guidance for the Full Year of 2022 Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
Investor sentiment deteriorated over the past week Jan 22
Now 22% undervalued after recent price drop Jan 19
Investor sentiment deteriorated over the past week Jan 06
Investor sentiment improved over the past week Nov 30
Third quarter 2021 earnings released: EPS US$0.47 (vs US$0.62 in 3Q 2020) Nov 11
Investor sentiment deteriorated over the past week Nov 10
Investor sentiment deteriorated over the past week Sep 12
Maravai LifeSciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $1 billion. Sep 11
Maravai LifeSciences Holdings, Inc. Provides Financial Guidance for the Year 2021 Aug 12
Second quarter 2021 earnings released: EPS US$0.44 (vs US$0.021 loss in 2Q 2020) Aug 12
Investor sentiment improved over the past week Aug 05
Co-Founder, President & Executive VP of Corporate Development Eric Tardif has left the company Jul 01 Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index
First quarter 2021 earnings released: EPS US$0.24 (vs US$0.021 loss in 1Q 2020) May 18 Shareholder Returns MAR DE Life Sciences DE Market 7D 2.5% 0.1% 0.3% 1Y -16.7% -5.3% 6.9%
See full shareholder returns
Return vs Market: MAR underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is MAR's price volatile compared to industry and market? MAR volatility MAR Average Weekly Movement 14.8% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MAR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MAR's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Show more Maravai LifeSciences Holdings, Inc. Fundamentals Summary How do Maravai LifeSciences Holdings's earnings and revenue compare to its market cap? MAR fundamental statistics Market cap €1.34b Earnings (TTM ) -€215.99m Revenue (TTM ) €266.23m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MAR income statement (TTM ) Revenue US$276.92m Cost of Revenue US$148.54m Gross Profit US$128.38m Other Expenses US$353.04m Earnings -US$224.66m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.58 Gross Margin 46.36% Net Profit Margin -81.13% Debt/Equity Ratio 85.1%
How did MAR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 13:20 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Michael Ryskin BofA Global Research Matthew Hewitt Craig-Hallum Capital Group LLC
Show 14 more analysts 